The Treat-to-target Study of RA Based on Smart System of Disease Management(SSDM)

Summary

This study evaluate the Smart System of Disease Management（SSDM）to improve the treat-to-target(T2T) and the safety of drug in the treatment of rheumatoid(RA). All participants will be randomized in the SSDM group and the control group. The patients in the SSDM group will use the SSDM every month and the control group will receive the conventional therapy.

Conditions

• Rheumatoid Arthritis

Interventions

OTHER

SSDM group

The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.

Sponsors & Collaborators

• Anhui Provincial Hospital

  collaborator OTHER_GOV

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Peking University International Hospital

  collaborator OTHER

• Xuanwu Hospital, Beijing

  collaborator OTHER

• Dongguan donghua hospital

  collaborator UNKNOWN

• Sixth Affiliated Hospital, Sun Yat-sen University

  collaborator OTHER

• Hebei General Hospital

  collaborator OTHER

• Bethune International Peace Hospital

  collaborator OTHER

• Central South University

  collaborator OTHER

• The First Affiliated Hospital with Nanjing Medical University

  collaborator OTHER

• Subei People's Hospital of Jiangsu Province

  collaborator OTHER

• The First Affiliated Hospital of BaoTou Medical College

  collaborator OTHER

• Linyi People's Hospital

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Mianyang Central Hospital

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• The First People's Hospital of Yunnan

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  collaborator OTHER

• Zhejiang Provincial People's Hospital

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• Xijing Hospital

  collaborator OTHER

• Tianjin First Central Hospital

  collaborator OTHER

• Peking University People's Hospital

  lead OTHER

Principal Investigators

• Chun Li, doctor · Peking University People's Hospital

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-11-01

Primary Completion

2020-05-29

Completion

2020-06-29

Countries

• China

Study Locations